Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sol Strategies has shown operational progress and institutional traction, but remains entirely dependent on volatile Solana ...

E.ON SE (EONGY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most ...

Zymeworks Inc. (ZYME) closed the last trading session at $12.08, gaining 2.9% over the past four weeks, but there could be ...

Explore the latest stock market movements with major stakes sold in Yes Bank, HDFC Bank's IPO plans, and strategic ...

Mind Medicine (NASDAQ: MNMD), a healthcare company that's looking to develop treatments based on psychedelic compounds, was something of a sleeper stock in May. Several positive developments pushed ...

Despite 9% YTD correction, cybersecurity stock remains above 200-DMA; only SME in Kedia's double-digit holdings list ...

The suspected irregularities have cost India’s fifth-largest lender, promoted by the Hindujas, more than just a Rs 2,300 ...

Discover the Jio Financial Services Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis ...

The S&P 500 eked out a gain of less than 0.1% on Wednesday, June 4, 2025, as soft results from a private payroll report ...

On Monday’s episode of Mad Money, host Jim Cramer broke down the day’s market movement and pointed out that Monday’s trading ...